CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with advanced prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to advanced prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/ international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to advanced prostate cancer.

8:00 am Welcome, Objectives, Agenda K. Chi
8:05 am Current and Upcoming Trials K. Chi

CUOG

AFFINITY A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer.

SYNERGY A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer.

AVIAS Multi Center Double Blind Study Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer.

continued on next page …
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.

**NCIC CTG**

**IND. 209** A Randomized Phase II Study Of Reolysin in Combination with Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients with Metastatic Castration Resistant Prostate Cancer.

**PRC.4** Alliance - phase III Enzalutamide + Abiraterone in castration resistant metastatic prostate cancer

**PR.17** ANZUP - ENZAMET - phase III testosterone suppression with or without Enzalutamide as first line metastatic prostate cancer.

8:15 am  **Trial Concepts**

**LIGAND** Repurposing drugs to exploit novel metabolic vulnerabilities of castrate sensitive Prostate Cancer.  
A. Joshua

A Phase II, randomized, multi-center study of cabazitaxel versus abiraterone or enzalutamide in poor prognosis-metastatic castration-resistant prostate cancer.  
K. Chi

8:25 am  **Needs, Opportunities and next steps**

- NEEDS: Post-ABI/ENZA and Pre-DOCE; Post-ABI/ENZA and Post-Chemo, combinations, predictive factors/correlative studies, others?
- OPPORTUNITIES: Cabozantinib, Radium-223, OGX-011, ARN-509, others?
- Next steps

9:00 am  **Meeting adjourned**